{"ticker": {"uuid": "fa621307-fa10-49b7-8abf-d5cc5855702d", "symbol": "BCDA", "name": "Biocardia\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOUnI0TkRNYndYQUoxd2sycTVSSkt5Q2FIVHFlTkp0MkFPV095QzhKN1lxbmFkblp5ZzZWU3VqT2ZYRVJtcDhOMWpQaUl6bmh3Um53NTBfT1ZnUVZzeFo4NndMMGtVOVVwTUtVN08tdkN3d0FWSjZZajVkWEVwS0p5VExQRW1sQnJhZVJhdFY0NlJYVkhOV1lGc0NmMGNrbVIxa0g3XzJYb1hwWEZh?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T20:16:45+00:00", "published_display": "20 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioCardia CEO Peter Altman buys $3,754 in company stock", "summary": "BioCardia CEO Peter Altman recently purchased 4,300 shares of company common stock for a total of $3,754, with individual share prices ranging from $0.86 to $0.88. This insider buying occurred despite a recent decline in the stock's value, which has fallen 16.91% in the past week", "url": "https://m.uk.investing.com/news/stock-market-news/biocardia-ceo-peter-altman-buys-3754-in-company-stock-93CH-4772759?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-16T08:12:26", "published_display": "16 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $3,754 in company stock By Investing.com", "summary": "BioCardia CEO Peter Altman recently purchased 4,300 shares of the company's common stock totaling $3,754, with individual transactions ranging from $0.86 to $0.88 per share. This insider buying follows a significant decline in the stock's value over the past year. The company is ", "url": "https://ca.investing.com/news/stock-market-news/biocardia-ceo-peter-altman-buys-3754-in-company-stock-93CH-4736171", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:18:38", "published_display": "15 Jul 2026 21:18", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 15 July By Investing.com", "summary": "This article reports a Form 4 filing for Biocardia Inc. on July 15th, 2026. Form 4s disclose transactions made by company insiders. The article includes the stock symbol BCDA, which was up 9.23% at the time of publication, and is a brief notice published by Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-15-july-93CH-4736175", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:18:38", "published_display": "15 Jul 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman adds 4,300 shares in July 2026 buying", "summary": "BioCardia, Inc. (BCDA) CEO Peter Altman purchased 4,300 shares of company common stock in open-market transactions in mid-July 2026. He bought 2,800 shares at $0.88 on July 14 and 1,500 shares at $0.86 on July 15, bringing his direct holdings to 368,385 shares. These transactions", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-07df8f3f7b73.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:18:38", "published_display": "15 Jul 2026 20:18", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioCardia president & CEO Peter Altman buys $7,175 in shares By Investing.com", "summary": "BioCardia's President and CEO, Peter Altman, recently purchased $7,175 worth of company shares over three days, increasing his direct ownership to 369,485 shares. These transactions occurred as the stock, BCDA, traded between $0.90 and $0.97, reflecting a nearly 24% drop over the", "url": "https://ng.investing.com/news/stock-market-news/biocardia-president--ceo-peter-altman-buys-7175-in-shares-93CH-2595701", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T01:09:12", "published_display": "11 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia president & CEO Peter Altman buys $7,175 in shares", "summary": "BioCardia's President and CEO, Peter Altman, recently purchased 7,500 shares of the company's stock for a total of $7,175, with prices ranging from $0.90 to $0.97 per share. This insider buying activity occurred as the stock's value decreased by nearly 24% over the previous week.", "url": "https://www.investing.com/news/insider-trading-news/biocardia-president--ceo-peter-altman-buys-7175-in-shares-93CH-4787103", "source_name": "Investing.com", "published_at": "2026-07-11T00:39:39", "published_display": "11 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Biocardia Inc. on July 10, 2026. The brief entry includes the stock symbol BCDA, which was up 2.47% at the time of publication, and an Investing.com byline.", "url": "https://ng.investing.com/news/stock-market-news/form-4-biocardiainc-for-10-july-93CH-2595711", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T23:26:00", "published_display": "10 Jul 2026 23:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman acquires 7,500 shares in open\u2011market buys", "summary": "BioCardia, Inc. President and CEO, Peter Altman, recently acquired 7,500 shares of common stock through open-market purchases between July 8-10, 2026. These transactions, valued at approximately $7,175, involved shares bought at prices ranging from $0.90 to $0.97, increasing his ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-5c89931b66c8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:39:39", "published_display": "10 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Biocardia Inc (BCDA) relating to activity on July 7th. The brief mention indicates that the company's stock experienced a -7.54% change. The content primarily serves as a placeholder for a financial filing update rath", "url": "https://ng.investing.com/news/stock-market-news/form-4-biocardiainc-for-7-july-93CH-2590148", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:44:50", "published_display": "08 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $5,208 in company stock", "summary": "Peter Altman, CEO of BioCardia, Inc. (NASDAQ:BCDA), recently purchased 5,400 shares of the company's common stock for a total of $5,208. This insider buying comes after the stock has seen a 15% decline in the past week and is trading significantly below its 52-week high, although", "url": "https://www.investing.com/news/insider-trading-news/biocardia-ceo-peter-altman-buys-5208-in-company-stock-93CH-4782222", "source_name": "Investing.com", "published_at": "2026-07-08T20:39:15", "published_display": "08 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 8 July By Investing.com", "summary": "This article from Investing.com is a simple announcement of a Form 4 filing for Biocardia Inc. on July 8th. It includes the stock symbol BCDA, which was down 4.93% at the time of publication, and a Reuters copyright. The content primarily serves as a placeholder for financial rep", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-8-july-93CH-4725760", "source_name": "Investing.com Canada", "published_at": "2026-07-08T19:40:14", "published_display": "08 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider buy: BioCardia (NASDAQ: BCDA) CEO adds 5,400 shares", "summary": "BioCardia, Inc.'s President and CEO, Peter Altman, purchased 5,400 shares of common stock on the open market at a weighted average price of $0.9645 per share. This transaction, executed through multiple trades ranging from $0.92 to $1.05 per share, increases his direct holdings t", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-08ca5479d53a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T19:39:15", "published_display": "08 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Altman has RSU tax shares withheld, receives new option grant", "summary": "BioCardia President and CEO Peter Altman underwent routine equity compensation activities. On July 2, 2026, 54,606 shares were withheld by the company to cover tax obligations on vested RSUs, which was not a market sale. Subsequently, on July 6, 2026, Altman received a grant of s", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-a581b6566ece.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:40:18", "published_display": "08 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Andrew Blank awarded 8,000 stock options at $1.20", "summary": "BioCardia (BCDA) director Andrew Scott Blank was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided he remains a service provider. Following this gr", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-e1085245fa7c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director granted 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Jim L. Allen was granted 8,000 stock options with an exercise price of $1.20 per share, as part of his compensation. These options will vest on the one-year anniversary of the grant date, provided he continues as a service provider. Following this award, ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-a92c9912093c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) SVP granted 29,442 options and has RSU shares withheld for taxes", "summary": "BioCardia, Inc.'s Senior Vice President, Devices, Edward M. Gillis, was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. Additionally, 17,269 common shares were withheld by BioCardi", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-341a4ad7b793.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Jay Moyes granted 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Jay M. Moyes was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. The options vest completely on the one-year anniversary of the grant date, provided Moyes remains a service provider. After this transaction,", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-131478454ab5.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Bill Facteau awarded 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Bill Facteau has been granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely on the one-year anniversary of the grant date, provided he remains a service provider. Following this", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-facb8f2c711a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Marvin Slosman awarded 8,000 stock options at $1.20", "summary": "BioCardia director Marvin Slosman was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely one year from the grant date, contingent on his continued service to the company. After this transaction, Slos", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-91c2cffdf193.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CFO awarded 41,501 options; shares withheld for tax", "summary": "BioCardia, Inc.'s CFO, David McClung, reported receiving 41,501 stock options with an exercise price of $1.20 per share, vesting monthly over 48 months from August 6, 2026. Additionally, 23,125 common shares were withheld by the company at $1.24 per share to cover tax obligations", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-3eb615a1c91e.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director receives 8,000 stock options exercisable at $1.20", "summary": "BioCardia, Inc. director Simon H. Stertzer was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided Stertzer continues as a service provider. After th", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-051003f5271b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman granted 110,625 fully vested RSUs", "summary": "BioCardia, Inc. CEO Peter Altman received an equity compensation award of 110,625 fully vested restricted stock units (RSUs) on June 29, 2026. These RSUs were granted as compensation in lieu of cash, valued at $1.20 per share, and increased his direct holdings to 411,191 shares. ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-6cf58a3a903e.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) SVP awarded 39,521 RSUs fully vesting on June 29, 2026", "summary": "BioCardia, Inc. (BCDA) Senior Vice President of Devices, Edward M. Gillis, was granted 39,521 restricted stock units (RSUs) as compensation. These RSUs, valued at $1.20 per share, fully vested on June 29, 2026, increasing his direct holdings to 71,395 shares of common stock. This", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-6c91239023e1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CFO granted 60,483 RSUs as stock compensation", "summary": "BioCardia Inc.'s Chief Financial Officer, David McClung, was granted 60,483 restricted stock units (RSUs) as compensation, which fully vested on June 29, 2026. This award, valued at $1.20 per share, increased his direct holdings to 137,370 shares. The transaction is categorized a", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-761a9a2fe036.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 1 July By Investing.com", "summary": "Investing.com reports on a Form 4 SEC filing by Biocardia Inc. for July 1st. The article provides the filing date and includes a general market overview with various indices, commodities, and stock performances.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-1-july-93CH-4717389", "source_name": "Investing.com Canada", "published_at": "2026-07-01T19:40:00", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCDA - BioCardia Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview of BioCardia Inc. (BCDA), including its latest stock performance, key financial metrics like market cap, income, and sales, and various valuation ratios. It also lists insider and institutional ownership, analyst recommendations", "url": "https://finviz.com/stock?t=BCDA&ty=lf&p=d&page=5", "source_name": "Finviz", "published_at": "2026-06-29T15:09:12", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Stertzer (BCDA) adds 109,200 BioCardia shares in open-market buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQm5XdUN5Rk5IRFltVXJzRFJRSGt0MGRhY3NsYUxjX3p2VkJaOFBZM0Y3WlJURjhHNmRWeXBrc29UT0YxbUJmNjdKQVV0U1U3V3JsU2ctS0VFOEdaREktM0JVNG1zNHptREJxN2VuSjBEdGNuVm9OaUYwTW0zb0FlcnVIOWtsVkRNSU4tUDRqaWI5MGxIR1o1NHlGUlJjd0tkdDQxRUhNeXgySWg0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO adds 2,300 shares in open-market buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOenpab1ZOVEdMRnVpRTZ5YVBOX3lkcTQtUnl6ZS1zM2JUeFU4d2NrT0FUVmdxVGFPWDR6R0h0ZjdERFhtUG5BTXB3RjN6T0M2bU1GWjl6ZWpuY0p0eHROU0hhZlhySUdBUFMwdUhHeFlwYWVzdnE0dXh2Z3ViblRYMWRWOW1tN0szS1VCNy1mQzlPR1VPRHpzd0lzX3F2Q3oxS1dYeXZvdkZJcnZY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biocardia-letter-stockholders-2026-priorities-120000033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia says Japan filing, U.S. trial enrollment top 2026 priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNY21raWYxWWxSQkJRYTd4N3F4YnZjU2tpaUl3TnFadzBwVEVrN2FyYnNialVweS1QaExxbk1rMHFDMXRuRmt6VmJpLVplYnM4Q3d3UDlOSXQ1UGhJTWpZV2VOVF95QW9OcUJKQmVtQVRvalBwZElYMXFkLW03dWhnSW9oUkxMYmpQdVpGSkQxLXZIY0h4RFIwcC1RVlQ4ODQtTERpU21zYnI2cVB6OExhcFhlLU1rcng4Wm9jakxB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Announces $4.4 Million Financing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biocardia-announces-4-4-million-120000039.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T12:00:00+00:00", "published_display": "08 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (NASDAQ: BCDA) extends cash runway with $4.4M equity raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ0RIblNSWjItVTlUTlF3Q2ZlZW50N1g0Q29XSVRiYzQxdkEzN3JiaXpNSTV5bGIxemFrdkJwMm5ySnN5ZDN6TVBuRURwa0liS2VtTDExd0lDUkc0QjZNMW1xcHJxOGtfNk1tblltMENpWW9Wd0hzdGhVelo1d0hMakxZNDlXV1hoQ1p1aVlMV3pSNjBTMUowLUc1b0NjeVVsWTNaemtn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia $4.4M raise to extend runway past Japan PMDA submission into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPazFuUWpjUi1UbDlqaVpIN0J3UHpuejdvWjFtM3lDWDZscHJxMHBLWS03dUJOeERoTHlIcjE5VEI3Y1VqZndHSG1fQURCTXJQQkdFOUlMSFNQb2VtUW5pVGVMTnhsSjJIVlkxMndGeGEyeFY1Q1RrSC1GOVhfN2MwYmpSTlZDcnlLcVZ6WU9nMVk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia stock surges on FDA trial pathway confirmation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOTd1YWQtaUdQWTVwRUQyR1Rqc29BN05nX2pkcDUxdUVVVWp1T2pfTVcydHpURXlXc2pGOU5IZ2VNSlc0NnBoOEJwejBKbjlrbFRDYUhNRTdhcnZuX3VMZy1sM0kwVzY0WXMzbVBjU2RKeTV5T2ZjUjNOd3pvdXdLM1I0NTlBcXd4SEVBcFJfU1FQTVJtd1NaTElIX05fSzBfWURTRkVYMHJNb0lrX3hSdlpjTmJmcHg5NHc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOFZiZnVZcWFVQUE0LVYyZVJIM1ZVUkU5ZEgwdGx3QWxRQ0FmWTVOSy1LeXBUZ3NPYkgxVWk3cEJUR2dsUXpJRXFwaVM0cFV1YzRabElZVDZUZnR2M0NiRDhwTkd5bUJRWENDeC1yWXN3THZRRTBab0NyLTAxVnpzQWRLSFNab2U4YTlXSjdtMU9SeC1OSkt4eERnRzNzNUpPZXlKWHNTNA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA minutes support BioCardia (NASDAQ: BCDA) CardiAMP HF II PMA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ0NxMmNjSWRsNGkzdFFzODFJWjJ0b2Jic3NGTjQ0Vm03bXBZSEJkeE1PMXBubjMtZ3dYQU5RX19JUmltam1JN3J4UEI0OFBENTcyTUE4T19MdGRpWktlODhOUGVTanBzTEd0dEFOZkpNd1hrVTRiMTBnSjU1aWlPNXlsa0QzSnJrNjBaZjl1bFRFRmJoN0pBRjlrTlA4TVp6M0pxNUVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioCardia CEO Peter Altman buys $1,230 in BCDA stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcE9TekJqR1lDUG5hSS1Lb3VlYS04akNWaUZJZ0FMZk5FNkdWVmdocHdtZUthN2FSWVRkMmlhOE1lczE5bzc4ZklVNFhUd2x4RE96b1A1S3RIbS05Z0ZHNmtpVDJOVFJUVk9ldUdNdmlkakZnLVNlYnF4SXBBc3o2ckNTSm1ZR3BDZHp4RmozWEd0UlEyUnRUYVFWbHNaZG1hSmJRNndNckFnSFR1dGhBa18wZGJQQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOUnI0TkRNYndYQUoxd2sycTVSSkt5Q2FIVHFlTkp0MkFPV095QzhKN1lxbmFkblp5ZzZWU3VqT2ZYRVJtcDhOMWpQaUl6bmh3Um53NTBfT1ZnUVZzeFo4NndMMGtVOVVwTUtVN08tdkN3d0FWSjZZajVkWEVwS0p5VExQRW1sQnJhZVJhdFY0NlJYVkhOV1lGc0NmMGNrbVIxa0g3XzJYb1hwWEZh?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T20:16:45+00:00", "published_display": "20 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $3,754 in company stock", "summary": "BioCardia CEO Peter Altman recently purchased 4,300 shares of company common stock for a total of $3,754, with individual share prices ranging from $0.86 to $0.88. This insider buying occurred despite a recent decline in the stock's value, which has fallen 16.91% in the past week", "url": "https://m.uk.investing.com/news/stock-market-news/biocardia-ceo-peter-altman-buys-3754-in-company-stock-93CH-4772759?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-16T08:12:26", "published_display": "16 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $3,754 in company stock By Investing.com", "summary": "BioCardia CEO Peter Altman recently purchased 4,300 shares of the company's common stock totaling $3,754, with individual transactions ranging from $0.86 to $0.88 per share. This insider buying follows a significant decline in the stock's value over the past year. The company is ", "url": "https://ca.investing.com/news/stock-market-news/biocardia-ceo-peter-altman-buys-3754-in-company-stock-93CH-4736171", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:18:38", "published_display": "15 Jul 2026 21:18", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 15 July By Investing.com", "summary": "This article reports a Form 4 filing for Biocardia Inc. on July 15th, 2026. Form 4s disclose transactions made by company insiders. The article includes the stock symbol BCDA, which was up 9.23% at the time of publication, and is a brief notice published by Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-15-july-93CH-4736175", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:18:38", "published_display": "15 Jul 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman adds 4,300 shares in July 2026 buying", "summary": "BioCardia, Inc. (BCDA) CEO Peter Altman purchased 4,300 shares of company common stock in open-market transactions in mid-July 2026. He bought 2,800 shares at $0.88 on July 14 and 1,500 shares at $0.86 on July 15, bringing his direct holdings to 368,385 shares. These transactions", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-07df8f3f7b73.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:18:38", "published_display": "15 Jul 2026 20:18", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia president & CEO Peter Altman buys $7,175 in shares By Investing.com", "summary": "BioCardia's President and CEO, Peter Altman, recently purchased $7,175 worth of company shares over three days, increasing his direct ownership to 369,485 shares. These transactions occurred as the stock, BCDA, traded between $0.90 and $0.97, reflecting a nearly 24% drop over the", "url": "https://ng.investing.com/news/stock-market-news/biocardia-president--ceo-peter-altman-buys-7175-in-shares-93CH-2595701", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T01:09:12", "published_display": "11 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia president & CEO Peter Altman buys $7,175 in shares", "summary": "BioCardia's President and CEO, Peter Altman, recently purchased 7,500 shares of the company's stock for a total of $7,175, with prices ranging from $0.90 to $0.97 per share. This insider buying activity occurred as the stock's value decreased by nearly 24% over the previous week.", "url": "https://www.investing.com/news/insider-trading-news/biocardia-president--ceo-peter-altman-buys-7175-in-shares-93CH-4787103", "source_name": "Investing.com", "published_at": "2026-07-11T00:39:39", "published_display": "11 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Biocardia Inc. on July 10, 2026. The brief entry includes the stock symbol BCDA, which was up 2.47% at the time of publication, and an Investing.com byline.", "url": "https://ng.investing.com/news/stock-market-news/form-4-biocardiainc-for-10-july-93CH-2595711", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T23:26:00", "published_display": "10 Jul 2026 23:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman acquires 7,500 shares in open\u2011market buys", "summary": "BioCardia, Inc. President and CEO, Peter Altman, recently acquired 7,500 shares of common stock through open-market purchases between July 8-10, 2026. These transactions, valued at approximately $7,175, involved shares bought at prices ranging from $0.90 to $0.97, increasing his ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-5c89931b66c8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:39:39", "published_display": "10 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Biocardia Inc (BCDA) relating to activity on July 7th. The brief mention indicates that the company's stock experienced a -7.54% change. The content primarily serves as a placeholder for a financial filing update rath", "url": "https://ng.investing.com/news/stock-market-news/form-4-biocardiainc-for-7-july-93CH-2590148", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:44:50", "published_display": "08 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $5,208 in company stock", "summary": "Peter Altman, CEO of BioCardia, Inc. (NASDAQ:BCDA), recently purchased 5,400 shares of the company's common stock for a total of $5,208. This insider buying comes after the stock has seen a 15% decline in the past week and is trading significantly below its 52-week high, although", "url": "https://www.investing.com/news/insider-trading-news/biocardia-ceo-peter-altman-buys-5208-in-company-stock-93CH-4782222", "source_name": "Investing.com", "published_at": "2026-07-08T20:39:15", "published_display": "08 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 8 July By Investing.com", "summary": "This article from Investing.com is a simple announcement of a Form 4 filing for Biocardia Inc. on July 8th. It includes the stock symbol BCDA, which was down 4.93% at the time of publication, and a Reuters copyright. The content primarily serves as a placeholder for financial rep", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-8-july-93CH-4725760", "source_name": "Investing.com Canada", "published_at": "2026-07-08T19:40:14", "published_display": "08 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider buy: BioCardia (NASDAQ: BCDA) CEO adds 5,400 shares", "summary": "BioCardia, Inc.'s President and CEO, Peter Altman, purchased 5,400 shares of common stock on the open market at a weighted average price of $0.9645 per share. This transaction, executed through multiple trades ranging from $0.92 to $1.05 per share, increases his direct holdings t", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-08ca5479d53a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T19:39:15", "published_display": "08 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Altman has RSU tax shares withheld, receives new option grant", "summary": "BioCardia President and CEO Peter Altman underwent routine equity compensation activities. On July 2, 2026, 54,606 shares were withheld by the company to cover tax obligations on vested RSUs, which was not a market sale. Subsequently, on July 6, 2026, Altman received a grant of s", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-a581b6566ece.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:40:18", "published_display": "08 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Andrew Blank awarded 8,000 stock options at $1.20", "summary": "BioCardia (BCDA) director Andrew Scott Blank was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided he remains a service provider. Following this gr", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-e1085245fa7c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director granted 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Jim L. Allen was granted 8,000 stock options with an exercise price of $1.20 per share, as part of his compensation. These options will vest on the one-year anniversary of the grant date, provided he continues as a service provider. Following this award, ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-a92c9912093c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) SVP granted 29,442 options and has RSU shares withheld for taxes", "summary": "BioCardia, Inc.'s Senior Vice President, Devices, Edward M. Gillis, was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. Additionally, 17,269 common shares were withheld by BioCardi", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-341a4ad7b793.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Jay Moyes granted 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Jay M. Moyes was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. The options vest completely on the one-year anniversary of the grant date, provided Moyes remains a service provider. After this transaction,", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-131478454ab5.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Bill Facteau awarded 8,000 stock options at $1.20", "summary": "BioCardia, Inc. director Bill Facteau has been granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely on the one-year anniversary of the grant date, provided he remains a service provider. Following this", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-facb8f2c711a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director Marvin Slosman awarded 8,000 stock options at $1.20", "summary": "BioCardia director Marvin Slosman was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely one year from the grant date, contingent on his continued service to the company. After this transaction, Slos", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-91c2cffdf193.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CFO awarded 41,501 options; shares withheld for tax", "summary": "BioCardia, Inc.'s CFO, David McClung, reported receiving 41,501 stock options with an exercise price of $1.20 per share, vesting monthly over 48 months from August 6, 2026. Additionally, 23,125 common shares were withheld by the company at $1.24 per share to cover tax obligations", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-3eb615a1c91e.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) director receives 8,000 stock options exercisable at $1.20", "summary": "BioCardia, Inc. director Simon H. Stertzer was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided Stertzer continues as a service provider. After th", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-051003f5271b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T02:10:59", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO Peter Altman granted 110,625 fully vested RSUs", "summary": "BioCardia, Inc. CEO Peter Altman received an equity compensation award of 110,625 fully vested restricted stock units (RSUs) on June 29, 2026. These RSUs were granted as compensation in lieu of cash, valued at $1.20 per share, and increased his direct holdings to 411,191 shares. ", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-6cf58a3a903e.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) SVP awarded 39,521 RSUs fully vesting on June 29, 2026", "summary": "BioCardia, Inc. (BCDA) Senior Vice President of Devices, Edward M. Gillis, was granted 39,521 restricted stock units (RSUs) as compensation. These RSUs, valued at $1.20 per share, fully vested on June 29, 2026, increasing his direct holdings to 71,395 shares of common stock. This", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-6c91239023e1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CFO granted 60,483 RSUs as stock compensation", "summary": "BioCardia Inc.'s Chief Financial Officer, David McClung, was granted 60,483 restricted stock units (RSUs) as compensation, which fully vested on June 29, 2026. This award, valued at $1.20 per share, increased his direct holdings to 137,370 shares. The transaction is categorized a", "url": "https://www.stocktitan.net/sec-filings/BCDA/form-4-bio-cardia-inc-insider-trading-activity-761a9a2fe036.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:32", "published_display": "01 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Biocardia Inc For: 1 July By Investing.com", "summary": "Investing.com reports on a Form 4 SEC filing by Biocardia Inc. for July 1st. The article provides the filing date and includes a general market overview with various indices, commodities, and stock performances.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biocardiainc-for-1-july-93CH-4717389", "source_name": "Investing.com Canada", "published_at": "2026-07-01T19:40:00", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCDA - BioCardia Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview of BioCardia Inc. (BCDA), including its latest stock performance, key financial metrics like market cap, income, and sales, and various valuation ratios. It also lists insider and institutional ownership, analyst recommendations", "url": "https://finviz.com/stock?t=BCDA&ty=lf&p=d&page=5", "source_name": "Finviz", "published_at": "2026-06-29T15:09:12", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Stertzer (BCDA) adds 109,200 BioCardia shares in open-market buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQm5XdUN5Rk5IRFltVXJzRFJRSGt0MGRhY3NsYUxjX3p2VkJaOFBZM0Y3WlJURjhHNmRWeXBrc29UT0YxbUJmNjdKQVV0U1U3V3JsU2ctS0VFOEdaREktM0JVNG1zNHptREJxN2VuSjBEdGNuVm9OaUYwTW0zb0FlcnVIOWtsVkRNSU4tUDRqaWI5MGxIR1o1NHlGUlJjd0tkdDQxRUhNeXgySWg0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (BCDA) CEO adds 2,300 shares in open-market buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOenpab1ZOVEdMRnVpRTZ5YVBOX3lkcTQtUnl6ZS1zM2JUeFU4d2NrT0FUVmdxVGFPWDR6R0h0ZjdERFhtUG5BTXB3RjN6T0M2bU1GWjl6ZWpuY0p0eHROU0hhZlhySUdBUFMwdUhHeFlwYWVzdnE0dXh2Z3ViblRYMWRWOW1tN0szS1VCNy1mQzlPR1VPRHpzd0lzX3F2Q3oxS1dYeXZvdkZJcnZY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biocardia-letter-stockholders-2026-priorities-120000033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia says Japan filing, U.S. trial enrollment top 2026 priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNY21raWYxWWxSQkJRYTd4N3F4YnZjU2tpaUl3TnFadzBwVEVrN2FyYnNialVweS1QaExxbk1rMHFDMXRuRmt6VmJpLVplYnM4Q3d3UDlOSXQ1UGhJTWpZV2VOVF95QW9OcUJKQmVtQVRvalBwZElYMXFkLW03dWhnSW9oUkxMYmpQdVpGSkQxLXZIY0h4RFIwcC1RVlQ4ODQtTERpU21zYnI2cVB6OExhcFhlLU1rcng4Wm9jakxB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Announces $4.4 Million Financing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biocardia-announces-4-4-million-120000039.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T12:00:00+00:00", "published_display": "08 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia (NASDAQ: BCDA) extends cash runway with $4.4M equity raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ0RIblNSWjItVTlUTlF3Q2ZlZW50N1g0Q29XSVRiYzQxdkEzN3JiaXpNSTV5bGIxemFrdkJwMm5ySnN5ZDN6TVBuRURwa0liS2VtTDExd0lDUkc0QjZNMW1xcHJxOGtfNk1tblltMENpWW9Wd0hzdGhVelo1d0hMakxZNDlXV1hoQ1p1aVlMV3pSNjBTMUowLUc1b0NjeVVsWTNaemtn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia $4.4M raise to extend runway past Japan PMDA submission into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPazFuUWpjUi1UbDlqaVpIN0J3UHpuejdvWjFtM3lDWDZscHJxMHBLWS03dUJOeERoTHlIcjE5VEI3Y1VqZndHSG1fQURCTXJQQkdFOUlMSFNQb2VtUW5pVGVMTnhsSjJIVlkxMndGeGEyeFY1Q1RrSC1GOVhfN2MwYmpSTlZDcnlLcVZ6WU9nMVk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia stock surges on FDA trial pathway confirmation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOTd1YWQtaUdQWTVwRUQyR1Rqc29BN05nX2pkcDUxdUVVVWp1T2pfTVcydHpURXlXc2pGOU5IZ2VNSlc0NnBoOEJwejBKbjlrbFRDYUhNRTdhcnZuX3VMZy1sM0kwVzY0WXMzbVBjU2RKeTV5T2ZjUjNOd3pvdXdLM1I0NTlBcXd4SEVBcFJfU1FQTVJtd1NaTElIX05fSzBfWURTRkVYMHJNb0lrX3hSdlpjTmJmcHg5NHc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOFZiZnVZcWFVQUE0LVYyZVJIM1ZVUkU5ZEgwdGx3QWxRQ0FmWTVOSy1LeXBUZ3NPYkgxVWk3cEJUR2dsUXpJRXFwaVM0cFV1YzRabElZVDZUZnR2M0NiRDhwTkd5bUJRWENDeC1yWXN3THZRRTBab0NyLTAxVnpzQWRLSFNab2U4YTlXSjdtMU9SeC1OSkt4eERnRzNzNUpPZXlKWHNTNA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA minutes support BioCardia (NASDAQ: BCDA) CardiAMP HF II PMA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ0NxMmNjSWRsNGkzdFFzODFJWjJ0b2Jic3NGTjQ0Vm03bXBZSEJkeE1PMXBubjMtZ3dYQU5RX19JUmltam1JN3J4UEI0OFBENTcyTUE4T19MdGRpWktlODhOUGVTanBzTEd0dEFOZkpNd1hrVTRiMTBnSjU1aWlPNXlsa0QzSnJrNjBaZjl1bFRFRmJoN0pBRjlrTlA4TVp6M0pxNUVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCardia CEO Peter Altman buys $1,230 in BCDA stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcE9TekJqR1lDUG5hSS1Lb3VlYS04akNWaUZJZ0FMZk5FNkdWVmdocHdtZUthN2FSWVRkMmlhOE1lczE5bzc4ZklVNFhUd2x4RE96b1A1S3RIbS05Z0ZHNmtpVDJOVFJUVk9ldUdNdmlkakZnLVNlYnF4SXBBc3o2ckNTSm1ZR3BDZHp4RmozWEd0UlEyUnRUYVFWbHNaZG1hSmJRNndNckFnSFR1dGhBa18wZGJQQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 47, "sentiment_summary": {"positive": 11, "negative": 1, "neutral": 35, "score": 54, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 87, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 3.71, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.83, "latest_week": "2026-07-17", "one_week_move": -9.7, "four_week_move": -14.6, "twelve_week_move": -28.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.366994, "market_dynamics_buy_signal": false, "relative_strength": -45.496923, "fair_value_gap": -77.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.2795, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.7% over one week, -14.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 22}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 5}, {"label": "Investing.com Canada", "count": 4}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Finviz", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 9}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.7% over one week, -14.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade"}], "updated_at": "2026-07-21T00:51:27.686386+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}